CLL Report: ASCO/EHA 2020
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL

Released: August 26, 2020

Expiration: August 25, 2021

John N. Allan
John N. Allan, MD
Jennifer R. Brown
Jennifer R. Brown, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:

  • ASCEND: acalabrutinib vs idelalisib plus rituximab or BR
  • ACE-CL-001: acalabrutinib long-term efficacy
  • CLL14: Venetoclax plus obinutuzumab
  • CLARITY: Ibrutinib plus venetoclax
  • Measurable residual disease (MRD)
  • Complex karyotypes
  • Zanubrutinib plus obinutuzumab and venetoclax

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://www.clinicaloptions.com/oncology/conference-coverage/global-asco-eha-2020